Trial Profile
Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin Lymphoma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms RIT
- 18 Apr 2013 New trial record